Elham Zarean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elham Zarean has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Hossein Amini-Khoei
Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences
2 shared publications - Zahra Lorigooini
Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 shared publications Ali Ahmadi
Modelling in Health Research Center and Department of Biostatics, Shahrekord University of Medical Sciences, Shahrekord, Iran
1 shared publication- Ali Ahmadi
Department of Epidemiology and Biostatistics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran
1 shared publication Alireza Baharizadeh
Sama Technical and Vocational Training College, Islamic Azad University, Shahrekord, Iran
1 shared publication- Antoni Sureda
Research Group in Community Nutrition and Oxidative Stress (NUCOX), University of Balearic Islands, 07122 Palma de Mallorca, Spain
1 shared publication
Latest Publications
- Open Access
- 4 September 2026
- Published by Springer Nature in BMC Psychology
Relationship between common non-communicable diseases (NCDs), risk factors and happiness in Shahrekord PERSIAN Cohort Study: a path analysis model in Iran
- 4 September 2026
- Published by Springer Nature in BMC Psychology
Open AccessRelationship between common non-communicable diseases (NCDs), risk factors and happiness in Shahrekord PERSIAN Cohort Study: a path analysis model in Iran
- 29 June 2025
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 27 (2) , 60-66
Possible involvement of the PI3K/Akt/mTOR signaling pathway in the antidepressant-like effects of modafinil in a mouse model of maternal separation stress
Background and aims: Depression is a widespread mental disorder. Maternal separation (MS) stress during early life increases the risk of depression. Modafinil (MOD) exhibits potential antidepressant-like properties, but its underlying molecular mechanisms remain unclear. The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway is implicated in neuropsychiatric disorders. This study aimed to investigate the role of the PI3K/Akt/mTOR pathway in the antidepressant-like effects of MOD in MS mice, offering potential insights into new therapeutic targets for depression treatment. Methods: In this study, 50 male NMRI mice were divided into five groups (n=10). The control group received normal saline, while the MS groups received normal saline and MOD at 25 mg/kg, 50 mg/kg, and 75 mg/kg for seven days. The counting open field test (OFT), forced swimming test (FST), and splash test were conducted to assess depression in rodents. The expression of PI3K, AKT, and mTOR genes was evaluated in the hippocampal tissue with real-time polymerase chain reaction (RT-PCR). Results: The results revealed that MS could induce depressive-like behaviors in mice. MOD administration significantly diminished immobility time in the FST at all doses (P<0.001) and amplified cleaning time in the splash test at doses of 25 mg/kg (P<0.01), 50 mg/kg (P<0.001), and 75 mg/kg (P<0.001). Additionally, MOD noticeably downregulated the expression of PI3K, AKT, and mTOR genes in the hippocampus at all doses (P<0.001). Conclusion: MOD possessed antidepressant-like properties in maternally separated mice. MOD could effectively ameliorate depressive-like behaviors and suppress the hippocampal expression of PI3K/AKT/mTOR genes. However, future studies are warranted to find the exact and more mechanisms of action of MOD in depression.
- 29 June 2025
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 27 (2) , 60-66
Possible involvement of the PI3K/Akt/mTOR signaling pathway in the antidepressant-like effects of modafinil in a mouse model of maternal separation stress
Background and aims: Depression is a widespread mental disorder. Maternal separation (MS) stress during early life increases the risk of depression. Modafinil (MOD) exhibits potential antidepressant-like properties, but its underlying molecular mechanisms remain unclear. The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway is implicated in neuropsychiatric disorders. This study aimed to investigate the role of the PI3K/Akt/mTOR pathway in the antidepressant-like effects of MOD in MS mice, offering potential insights into new therapeutic targets for depression treatment. Methods: In this study, 50 male NMRI mice were divided into five groups (n=10). The control group received normal saline, while the MS groups received normal saline and MOD at 25 mg/kg, 50 mg/kg, and 75 mg/kg for seven days. The counting open field test (OFT), forced swimming test (FST), and splash test were conducted to assess depression in rodents. The expression of PI3K, AKT, and mTOR genes was evaluated in the hippocampal tissue with real-time polymerase chain reaction (RT-PCR). Results: The results revealed that MS could induce depressive-like behaviors in mice. MOD administration significantly diminished immobility time in the FST at all doses (P<0.001) and amplified cleaning time in the splash test at doses of 25 mg/kg (P<0.01), 50 mg/kg (P<0.001), and 75 mg/kg (P<0.001). Additionally, MOD noticeably downregulated the expression of PI3K, AKT, and mTOR genes in the hippocampus at all doses (P<0.001). Conclusion: MOD possessed antidepressant-like properties in maternally separated mice. MOD could effectively ameliorate depressive-like behaviors and suppress the hippocampal expression of PI3K/AKT/mTOR genes. However, future studies are warranted to find the exact and more mechanisms of action of MOD in depression.
- 17 November 2024
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 25 (10) , 592-603
Exploring the anti-depressant effects and nitric oxide modulation of quercetin: A preclinical study in Socially Isolated mice
This study investigates the effects of quercetin, an antioxidant and nitric oxide (NO) modulator, on depressive-like behaviours triggered by social isolation stress (SIS) in mice. SIS, known to harm psychosocial functioning and increase the risk of depression, involves oxidative stress and NO in its pathophysiology. 72 male mice were divided into nine groups, including the social (SC) group as the control group (stress-free with normal saline intake). The isolation (IC) groups received normal saline, quercetin at doses of 10, 20, and 40 mg/kg, the nitric oxide synthetase inhibitor L-NAME at a dose of 5 mg/kg, the NO precursor L-arginine at a dose of 100 mg/kg, an ineffective dose of quercetin combined with L-NAME and an effective dose of quercetin combined with L-arginine. Behavioural tests (open-field, forced swimming, and splash tests) were conducted, followed by measuring hippocampal nitrite levels. Quercetin significantly reduced immobility in the forced swimming test, increased activity in the open-field test, and enhanced grooming behaviour, particularly at 40 mg/kg. Co-administration of an ineffective dose of quercetin (10 mg/kg) with L-NAME increased immobility and grooming activity time. Interestingly, co-administration of the effective dose of quercetin (40 mg/kg) with L-arginine increased immobility time in the FST. Additionally, administration of quercetin at doses of 20 and 40 mg/kg significantly reduced the nitrite level in the hippocampus of SIS mice. Furthermore, co-administration of L-NAME and L-arginine with ineffective and effective doses of quercetin decreased and increased nitrite levels in the hippocampus and increased immobility time in the FST compared to their respective counterparts administered alone. These results suggest quercetin's potential in alleviating depression by modulating NO levels, pointing to its promise in treating depression associated with chronic stressors like social isolation.
- 17 November 2024
- Published by Taylor & Francis in The World Journal of Biological Psychiatry
- Vol. 25 (10) , 592-603
Exploring the anti-depressant effects and nitric oxide modulation of quercetin: A preclinical study in Socially Isolated mice
This study investigates the effects of quercetin, an antioxidant and nitric oxide (NO) modulator, on depressive-like behaviours triggered by social isolation stress (SIS) in mice. SIS, known to harm psychosocial functioning and increase the risk of depression, involves oxidative stress and NO in its pathophysiology. 72 male mice were divided into nine groups, including the social (SC) group as the control group (stress-free with normal saline intake). The isolation (IC) groups received normal saline, quercetin at doses of 10, 20, and 40 mg/kg, the nitric oxide synthetase inhibitor L-NAME at a dose of 5 mg/kg, the NO precursor L-arginine at a dose of 100 mg/kg, an ineffective dose of quercetin combined with L-NAME and an effective dose of quercetin combined with L-arginine. Behavioural tests (open-field, forced swimming, and splash tests) were conducted, followed by measuring hippocampal nitrite levels. Quercetin significantly reduced immobility in the forced swimming test, increased activity in the open-field test, and enhanced grooming behaviour, particularly at 40 mg/kg. Co-administration of an ineffective dose of quercetin (10 mg/kg) with L-NAME increased immobility and grooming activity time. Interestingly, co-administration of the effective dose of quercetin (40 mg/kg) with L-arginine increased immobility time in the FST. Additionally, administration of quercetin at doses of 20 and 40 mg/kg significantly reduced the nitrite level in the hippocampus of SIS mice. Furthermore, co-administration of L-NAME and L-arginine with ineffective and effective doses of quercetin decreased and increased nitrite levels in the hippocampus and increased immobility time in the FST compared to their respective counterparts administered alone. These results suggest quercetin's potential in alleviating depression by modulating NO levels, pointing to its promise in treating depression associated with chronic stressors like social isolation.
- Open Access
- 27 January 2021
- Published by Springer Nature in Middle East Current Psychiatry
- Vol. 28 (1) , 1-8
Association between depression, anxiety, and insomnia with musculoskeletal pain source: a multi-center study
Background: Musculoskeletal pain syndrome (MPS) is one of the modern diseases. Musculoskeletal pain (MP) may develop at any age and impact physical and mental health. This study aimed to evaluate the association between anxiety, depression, and insomnia with musculoskeletal pain source. This cross-sectional study was conducted on 450 patients with musculoskeletal pain. Goldberg depression (GB), Beck Anxiety Inventory (BAI), and Morin Insomnia Severity Index (ISI) questionnaires were used to collect data. Participants have divided into two groups: individuals with unknown musculoskeletal pain sources and individuals with known musculoskeletal pain sources. Anxiety, depression, and insomnia scores were compared between the two groups. For statistical analysis of data mean (SD), frequency (%), Chi-square, Mann-Whitney test, and Logistic regression models were used. All analysis was performed using SPSS 26. Results: In this study, 39.4% of the participants were in severe depression, 31.1% in severe anxiety, 34.7% in the no clinically significant, and 32.9% in the sub-threshold insomnia group. There was a significant difference between the severity of anxiety and insomnia in the two groups with the known and unknown pain sources (p < 0.05). However, the score of depression (OR = 1.00, 95% CI 0.99–1.01), anxiety (OR = 1.00, 95% CI 0.99–1.02), and insomnia (OR = 1.01, 95% CI 0.98–1.03) was not related to the pain source. Conclusion: There was a statistically significant relationship between anxiety and insomnia severity with musculoskeletal pain source. According to the high prevalence of depression, anxiety, and depression in both groups with known and unknown musculoskeletal pain sources, the cooperation of orthopedists, rheumatologists, and physical therapists with psychiatrist can be useful in improving the condition of patients.
- 27 January 2021
- Published by Springer Nature in Middle East Current Psychiatry
- Vol. 28 (1) , 1-8
Open AccessAssociation between depression, anxiety, and insomnia with musculoskeletal pain source: a multi-center study
Background: Musculoskeletal pain syndrome (MPS) is one of the modern diseases. Musculoskeletal pain (MP) may develop at any age and impact physical and mental health. This study aimed to evaluate the association between anxiety, depression, and insomnia with musculoskeletal pain source. This cross-sectional study was conducted on 450 patients with musculoskeletal pain. Goldberg depression (GB), Beck Anxiety Inventory (BAI), and Morin Insomnia Severity Index (ISI) questionnaires were used to collect data. Participants have divided into two groups: individuals with unknown musculoskeletal pain sources and individuals with known musculoskeletal pain sources. Anxiety, depression, and insomnia scores were compared between the two groups. For statistical analysis of data mean (SD), frequency (%), Chi-square, Mann-Whitney test, and Logistic regression models were used. All analysis was performed using SPSS 26. Results: In this study, 39.4% of the participants were in severe depression, 31.1% in severe anxiety, 34.7% in the no clinically significant, and 32.9% in the sub-threshold insomnia group. There was a significant difference between the severity of anxiety and insomnia in the two groups with the known and unknown pain sources (p < 0.05). However, the score of depression (OR = 1.00, 95% CI 0.99–1.01), anxiety (OR = 1.00, 95% CI 0.99–1.02), and insomnia (OR = 1.01, 95% CI 0.98–1.03) was not related to the pain source. Conclusion: There was a statistically significant relationship between anxiety and insomnia severity with musculoskeletal pain source. According to the high prevalence of depression, anxiety, and depression in both groups with known and unknown musculoskeletal pain sources, the cooperation of orthopedists, rheumatologists, and physical therapists with psychiatrist can be useful in improving the condition of patients.
- Open Access
- 29 June 2020
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 22 (3) , 141-145
The effect of traditional music on mental status of chronic schizophrenic patients: a clinical trial study
Background and aims: Music therapy is a simple and inexpensive method for the treatment of some psychiatric disorders. The aim of this study was to determine the effect of traditional music on the mental state of hospitalized chronic schizophrenia patients. Methods: In this clinical trial, 30 schizophrenia patients in the intervention group received routine treatment and attended music therapy sessions and 30 patients in the control group received routine treatment alone. Group music therapy sessions with traditional music were conducted 5 times a week for 2 months. Demographic questionnaire and Andreasen’s positive and negative symptoms questionnaires were completed at baseline and after the completion of music therapy sessions. Data analysis was conducted in SPSS version 16.0 using independent and paired t tests. Results: The mean scores of delusion (P=0.001) and bizarre behavior (P=0.036) and the total score of the SAPS (P=0.001) significantly decreased after intervention in the music therapy group. However, in the control group, the differences in the total and individual domain scores of the SAPS were not significant (P>0.05). There was no significant difference between the control and music therapy groups in the total and individual domain scores of the Scale for the Assessment of Negative Symptoms (SANS) before and after the intervention (P>0.05). Additionally, before and after the study, the mean score of avolition in the music therapy group was significantly lower compared to the control group (P=0.03). The mean score of alogia in the music therapy group was significantly lower compared to the control group (P=0.01). Conclusion: Music therapy is effective in improving most of the positive symptoms of schizophrenia and some of its negative aspects, and therefore can be used as a complementary therapy along with drug therapy.
- 29 June 2020
- Published by Maad Rayan Publishing Company in Journal of Shahrekord University of Medical Sciences
- Vol. 22 (3) , 141-145
Open AccessThe effect of traditional music on mental status of chronic schizophrenic patients: a clinical trial study
Background and aims: Music therapy is a simple and inexpensive method for the treatment of some psychiatric disorders. The aim of this study was to determine the effect of traditional music on the mental state of hospitalized chronic schizophrenia patients. Methods: In this clinical trial, 30 schizophrenia patients in the intervention group received routine treatment and attended music therapy sessions and 30 patients in the control group received routine treatment alone. Group music therapy sessions with traditional music were conducted 5 times a week for 2 months. Demographic questionnaire and Andreasen’s positive and negative symptoms questionnaires were completed at baseline and after the completion of music therapy sessions. Data analysis was conducted in SPSS version 16.0 using independent and paired t tests. Results: The mean scores of delusion (P=0.001) and bizarre behavior (P=0.036) and the total score of the SAPS (P=0.001) significantly decreased after intervention in the music therapy group. However, in the control group, the differences in the total and individual domain scores of the SAPS were not significant (P>0.05). There was no significant difference between the control and music therapy groups in the total and individual domain scores of the Scale for the Assessment of Negative Symptoms (SANS) before and after the intervention (P>0.05). Additionally, before and after the study, the mean score of avolition in the music therapy group was significantly lower compared to the control group (P=0.03). The mean score of alogia in the music therapy group was significantly lower compared to the control group (P=0.01). Conclusion: Music therapy is effective in improving most of the positive symptoms of schizophrenia and some of its negative aspects, and therefore can be used as a complementary therapy along with drug therapy.